Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Deutsch

Showing results (61-70 of 351) with videos related to

Pageof 36
Sort By:
Methods (San Diego, Calif.)|July 23, 2020
Reinventing radiation therapy with machine learning and imaging bio-markers (radiomics): State-of-the-art, challenges and perspectivesLaurent Dercle, Theophraste Henry, Alexandre Carré, et al.
Journal of Proteome Research|October 5, 2011
jTraML: an open source Java API for TraML, the PSI standard for sharing SRM transitionsKenny Helsens, Mi-Youn Brusniak, Eric Deutsch, et al.
Investigational New Drugs|July 20, 2012
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft modelsCéline Clémenson, Erwan Jouannot, Ana Merino-Trigo, et al.
Nature Reviews. Clinical Oncology|July 15, 2009
Are RAS mutations predictive markers of resistance to standard chemotherapy?Yohann Loriot, Pierre Mordant, Eric Deutsch, et al.
Presse Medicale (Paris, France : 1983)|August 27, 2013
Complications of thoracic radiotherapyCyrus Chargari, François Riet, Marianne Mazevet, et al.
International Review of Cell and Molecular Biology|March 30, 2023
Impact of radiation therapy on healthy tissuesCyrus Chargari, Elie Rassy, Carole Helissey, et al.
Critical Reviews in Oncology/Hematology|October 6, 2012
Radiation therapy and immunotherapy: implications for a combined cancer treatmentAntonin Levy, Cyrus Chargari, Morgane Cheminant, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2016
Can immunostimulatory agents enhance the abscopal effect of radiotherapy?Antonin Levy, Cyrus Chargari, Aurelien Marabelle, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2013
Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcomeGabriel G Malouf, Odile Casiraghi, Eric Deutsch, et al.
Investigational New Drugs|January 17, 2012
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapyCéline Clémenson, Cyrus Chargari, Laurent Désiré, et al.
Pageof 36

Showing results (61-70 of 351) with videos related to

Sort By:
Pageof 36
Methods (San Diego, Calif.)|July 23, 2020
Reinventing radiation therapy with machine learning and imaging bio-markers (radiomics): State-of-the-art, challenges and perspectivesLaurent Dercle, Theophraste Henry, Alexandre Carré, et al.
Journal of Proteome Research|October 5, 2011
jTraML: an open source Java API for TraML, the PSI standard for sharing SRM transitionsKenny Helsens, Mi-Youn Brusniak, Eric Deutsch, et al.
Investigational New Drugs|July 20, 2012
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft modelsCéline Clémenson, Erwan Jouannot, Ana Merino-Trigo, et al.
Nature Reviews. Clinical Oncology|July 15, 2009
Are RAS mutations predictive markers of resistance to standard chemotherapy?Yohann Loriot, Pierre Mordant, Eric Deutsch, et al.
Presse Medicale (Paris, France : 1983)|August 27, 2013
Complications of thoracic radiotherapyCyrus Chargari, François Riet, Marianne Mazevet, et al.
International Review of Cell and Molecular Biology|March 30, 2023
Impact of radiation therapy on healthy tissuesCyrus Chargari, Elie Rassy, Carole Helissey, et al.
Critical Reviews in Oncology/Hematology|October 6, 2012
Radiation therapy and immunotherapy: implications for a combined cancer treatmentAntonin Levy, Cyrus Chargari, Morgane Cheminant, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2016
Can immunostimulatory agents enhance the abscopal effect of radiotherapy?Antonin Levy, Cyrus Chargari, Aurelien Marabelle, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2013
Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcomeGabriel G Malouf, Odile Casiraghi, Eric Deutsch, et al.
Investigational New Drugs|January 17, 2012
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapyCéline Clémenson, Cyrus Chargari, Laurent Désiré, et al.
Pageof 36